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Abstract
Group B streptococcus (GBS) has emerged as an important
cause of invasive infection in adults. Here, we report the clinical
and microbiological characteristics of 401 non-redundant GBS
strains causing adult invasive infections collected during a 4-year
period (2007–2010). Bacteraemia without focus (43.4%) and
bone and joint infections (18.7%) were the main clinical manifes-
tations. The distribution of capsular polysaccharide (CPS) type
showed that types Ia, III, and V accounted for 71.8% of all
strains. Resistance to erythromycin increased from 20.2% in
2007 to 35.3% in 2010, and was mainly associated with CPS
type V harbouring the erm(B) resistant determinant.
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Group B streptococcus (GBS) has emerged as an important
cause of invasive infection in adults [1–6]. We report here
the clinical and microbiological characteristics of 401 non-
redundant GBS strains causing adult invasive infections col-
lected during a 4-year period (2007–2010). GBS strains were
sent to the CNR-Strep, and epidemiological and clinical
information was abstracted from questionnaires sent with
the strain. A case of invasive disease was deﬁned as the iso-
lation of GBS in any sample obtained from a normally sterile
site (e.g. blood, cerebrospinal ﬂuid, joint, bone, synovial ﬂuid,
or pleural ﬂuid) in a patient aged ‡18 years. Bacteraemia was
considered to be without focus when no source of infection
could be identiﬁed. All strains were identiﬁed as GBS on the
basis of colony morphology, b-haemolysis on horse blood
agar plates (bioMe´rieux, Marcy l’Etoile, France), Gram stain-
ing, and Lanceﬁeld grouping with type B antisera (Oxoid,
Basingstoke, UK). Molecular capsular polysaccharide (CPS)
typing was performed with a multiplex PCR assay, as previ-
ously described [7]. Susceptibility testing of antibiotics was
performed according to CLSI recommendations. Detection
of antibiotic resistance genes was performed with a multiplex
PCR assay [8]. Statistical analysis was performed according
to two-tailed Fischer’s exact and v2-tests. A p-value of <0.05
was considered to be statistically signiﬁcant.
A total of 401 cases of GBS adult invasive infections were
analysed. The median age of the patients was 61 years
(range, 18–103 years), and 51.9% were male (Table 1). GBS
strains were isolated primarily from blood (81.5%), but also
from joint or bone (15.9%), cerebrospinal ﬂuid (4.9%), or
other specimens (4.2%). The clinical characteristics of adult
invasive GBS infections are shown in Table 1. Disease pri-
marily presented as bacteraemia without focus, correspond-
ing to 43.4% of the cases, but was signiﬁcantly more
frequent among the 18–39-year age group (65.6%;
p <0.0001), among which 23 (54.8%) GBS diseases were
pregnancy-related. Bone and joint infections constituted the
second most common GBS infection (75/401, 18.7%); the
median age of the patients was 57.7 years (range, 21–
87 years), and 57.3% (43/75) were male. Skin and soft tissue
infections occurred in 48 cases (12%), with a higher inci-
dence in patients aged ‡65 years (14.1%) than in patients
aged 18–39 years (4.6%; p 0.003). Erysipelas accounted for
31% of these infections; the median age of the patients was
71 years (range, 43–88 years), and 51.7% were males. Endo-
carditis was diagnosed in 42 (10.5%) patients according to
Duke’s modiﬁed criteria [9]. The median age of the patients
with endocarditis was 68.4 years (range, 34–87 years), and
52.4% were male. Meningitis accounted for 5.2% of the cases;
the median age of the patients was 51 years (range, 26–
82 years), and 43% were male (data not shown). Respiratory
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tract infections (4%), peritonitis (3.2%) and urinary tract
infections (3%) accounted for the remaining GBS diseases.
A CPS type was assigned to all strains except one, owing
to a deletion in the cps locus, as previously described [7]
(Table 2). The most prevalent CPS types were types III
(25.7%), V (23.4%), and Ia (22.7%), which together accounted
for 71.8% of cases (Table 2). CPS types Ib (10.5%), II
(11.2%), IV (4.7%), VII (1%) and VI (0.5%) accounted for the
remaining 27.9% of cases. Stratiﬁed by age, CPS type V was
predominant in the 40–64-year and >65-year age groups,
whereas CPS type III was predominant in the 18–39-year age
group, most of these cases (23/64; 36%) being related to
pregnancy (Table 2).
All strains were susceptible to penicillin, amoxycillin, cefo-
taxime, imipenem, rifampicin, and vancomycin, and displayed
low-level resistance to gentamicin. Resistance to erythro-
mycin increased during the study period, from 20% in 2007 to
35.3% in 2010 (p 0.0099). Globally, erythromycin resistance
was detected in 31% (124/401) of all strains (Table 2), and
was 4.6 times more likely to occur (p <0.0001) in CPS type V
strains (48.4%) than in other CPS types (median, 11%; range,
5.6–13.7%). Clindamycin resistance was detected in 23% of
the strains and, as observed for erythromycin resistance, CPS
type V accounted for 53.7% of clindamycin-resistant strains
(p <0.0001). A signiﬁcant association of erythromycin resis-
tance and skin and soft tissue infection (p 0.0009) or bone
and join infection (p 0.027) was also observed(not shown).
Among the 124 erythromycin-resistant strains, 64.5% (80/
124) were constitutively resistant to clindamycin [constitu-
tive macrolide, lincosamide and streptogramin B resistance
(cMLS)], 18.5% (23/124) showed an inducible clindamycin
resistance phenotype [inducible macrolide, lincosamide and
streptogramin B resistance (iMLS)], and 16.7% (21/124)
showed a macrolide-resistant but clindamycin-susceptible and
streptogramin B-susceptible (M) phenotype.
Genetic analysis of erythromycin and clindamycin resis-
tance genes showed that all strains with the M phenotype
contained mef only (21/124). Among the 80 strains with the
cMLS phenotype, 67.5% (54/80) harboured erm(B) and 32.5%
(26/80) erm(A). Among the 23 strains with the iMLS pheno-
type, erm(B) and erm(A) were detected in 4.3% (1/23) and
87% (20/23) of strains, respectively, and 8.7% (2/23) of
strains tested negative for both erythromycin resistance
genes (not shown). The mef gene was signiﬁcantly associated
TABLE 1. Characteristics of adults
with invasive group B streptococ-
cal infections (2007–2010)
Variable
No. of cases (%)
All, n = 401
(100)
18–39 years,
n = 64 (16)
40–64 years,
n = 125 (31.2)
‡65 years,
n = 212 (52.8)
Male gender 208 (51.9) 22 (34.4) 75 (60) 111 (53.4)
Female gender 193 (48.1) 42 (65.6) 50 (40) 101 (47.6)
Age, median years 61 31 53 79
Clinical syndrome
Bacteraemia without focus 174 (43.4) 42 (65.6) 39 (31.2) 93 (43.9)
Bone and joint infection 75 (18.7) 11 (17.2) 32 (25.6) 32 (15)
Skin and/or soft tissue infection 48 (12) 3 (4.6) 15 (12) 30 (14.1)
Endocarditis 42 (10.5) 1 (1.6) 15 (12) 26 (12.3)
Meningitis 21 (5.2) 6 (9.4) 10 (8) 5 (2.4)
Respiratory tract infection 16 (4) 1 (1.6) 4 (3.2) 11 (5.2)
Peritonitis 13 (3.2) 0 (0.0) 6 (4.8) 7 (3.3)
Urinary tract infection 12 (3) 0 (0.0) 4 (3.2) 8 (3.8)
TABLE 2. Characterization of mac-
rolide-resistant group B strepto-
coccal strains according to capsular
polysaccharide (CPS) type
No. of strains (%)
Phenotypic pattern Resistance gene
CPS type EryR EryR CliR erm(A) erm(B) mef(A)
Total 401 (100) 124 (31) 80 (23) 46 (37) 57 (46) 21 (17)
Ia 91 (22.7) 17 (13.7) 1 (1.2) 1 (2.1) 2 (3.5) 16 (76.2)
Ib 42 (10.5) 12 (9.6) 9 (11.2) 9 (19.6) 3 (5.3) 0 (0)
II 45 (11.2) 14 (11.3) 12 (15) 3 (6.5) 11 (19.3) 0 (0)
III 103 (25.7) 14 (11.3) 9 (11.2) 5 (10.8) 7 (12.3) 2 (9.5)
IV 19 (4.7) 7 (5.6) 6 (7.5) 5 (71.4) 1 (1.75) 1 (4.8)
V 94 (23.4) 60 (48.4) 43 (53.7) 23 (39.6) 33 (57.9) 2 (9.5)
VI 2 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VII 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
NT 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
NT, non-typable.
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with CPS type Ia (76.2%, 16/21) as compared with all other
CPS types (p <0.0001).
Seventy-nine per cent of the strains (320/401) were phe-
notypically resistant to tetracycline (MIC >8 mg/L). Among
these strains, tet(M), tet(O) and tet(L) accounted for 93.75%
(300/320), 5% (16/300), and 0.3% (1/320), respectively, and
the search for tet(M), tet(O) tet(K) and tet(L) gave negative
results for three strains (not shown). Interestingly, 14 strains
that were phenotypically susceptible to tetracycline
(MIC <8 mg/L) were tet(M)-positive.
In conclusion, this study provides the clinical and microbio-
logical characteristics of GBS strains isolated from adult inva-
sive infections in France. From these data, we show that: (i)
GBS invasive infections in adults are more frequent among
people ‡65 years of age, as described in other European and
US surveys [1–6]; (ii) CPS types Ia, III and V accounted for 72%
of all strains, a distribution similar to those observed in other
countries [1–6]; (iii) resistance to erythromycin increased
from 2007, reaching 35.24% in 2010, and was strongly associ-
ated with CPS type V; and (iv) the mef genotype was associ-
ated with CPS type Ia GBS. Continued surveillance of invasive
GBS disease in adults and genetic characterization of isolated
strains are necessary, as this might impact on strategies related
to antibiotic use and vaccine design.
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Abstract
A 24-year-old female patient developed sepsis resulting from
preoperative administration of probiotics following an aortic
valve replacement. Blood cultures revealed the causative agent
to be the probiotic Lactobacillus rhamnosus, which has recently
been implicated as an emerging aetiology of infection in those
taking probiotics. In the past few years, probiotic use in hospitals
has increased greatly. However, there is growing global evidence
that the use of probiotics in patients with organ failure, immuno-
compromised status and dysfunctional gut barrier mechanisms
can cause infections. This and other reports show the impor-
tance of establishing generally recognized safety guidelines.
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